ZIM
FATE icon

Zacks Investment Management’s Fate Therapeutics FATE Stock Holding History

Zacks Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-55,515
Closed -$2.22M – 539
2020
Q3 		$2.22M Sell
55,515
-2,401
-4% -$83.8K 0.05% 212
2020
Q2 		$1.99M Sell
57,916
-16,567
-22% -$494K 0.04% 200
2020
Q1 		$1.65M Sell
74,483
-9,093
-11% -$230K 0.04% 217
2019
Q4 		$1.64M Buy
+83,576
New +$1.33M 0.03% 305

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Zacks Investment Management's FATE Position: Q4 2020 in Review

Zacks Investment Management sold out of Fate Therapeutics (FATE) in Q4 2020, closing a stake of 55,515 shares — an estimated $2.22M sold.

Zacks Investment Management first reported a position in FATE in Q4 2019 and held it in 4 quarters. The position peaked at $2.22M in Q3 2020. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • Zacks Investment Management reported no remaining Fate Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Zacks Investment Management sold 55,515 Fate Therapeutics shares in Q4 2020, an estimated $2.22M.
  • Zacks Investment Management first reported a position in Fate Therapeutics in Q4 2019 and held it in 4 quarters.
  • Zacks Investment Management's Fate Therapeutics position peaked at $2.22M in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Zacks Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.